Surgery – Magnetic field applied to body for therapy – Electromagnetic coil
Reexamination Certificate
1999-11-11
2002-04-02
Lacyk, John P. (Department: 3736)
Surgery
Magnetic field applied to body for therapy
Electromagnetic coil
C600S015000
Reexamination Certificate
active
06364824
ABSTRACT:
TECHNICAL FIELD
The present invention relates to stimulating cell receptor activity, and more particularly, to using electromagnetic fields to stimulate cell receptor activity.
BACKGROUND
Osteoporosis is a disease characterized by a decrease in bone mass which leads to spontaneous bone fractures or a bone fracture occurring due to an impact that under normal conditions would not produce a bone fracture. The goal for treating osteoporosis is to build bone strength to a level sufficient to withstand normal loading conditions without failure.
A significant determinant: of bone strength is bone mass. Bone mass is determined by the balance between the activity of osteoclast, which destroy bone, and osteoblast, which build bone. During homeostasis, in which bone mass is maintained at a constant level, the activity of the osteoclast and osteoblast are equal. The amount of bone being turned over by the activity of bone cells is 5-10% per year.
At approximately age 30 peak bone mass is achieved. At this stage the activity of osteoblasts begin to lag behind the activity of osteoclasts. This results in a loss of bone. The rate of bone loss varies between individuals but is generally greater in women when expressed as a percent of total bone compared to men. Furthermore, the drop in estrogen levels at menopause is accompanied by an increase in osteoclast activity. Estrogen is believed to act as a brake on osteoclast activity. The activity of osteoblast also increases but not to the same extent as the increase in osteoclast activity. The result is an even greater rate in the loss of bone compared with the pre-menopausal rate.
The health impact of osteoporosis includes loss of the quality of life as osteoporotic bone fractures usually occur in the elder who have a diminished healing capacity. Furthermore, approximately 20% of elderly women who suffer from an osteoporotic hip fracture will die within the next year. The health care cost due to osteoporosis is between 5 and 10 billion dollars per year in the United States.
Treatment of osteoporosis has focused on two fronts. One is inhibition of ostecclast to prevent further resorption of bone and the second is to stimulate osteoblast to form new bone. Osteoporosis therapies targeted at preventing bone resorption, include Hormone Replacement Therapy (HRT) which replaces the lost estrogen with therapeutic estrogen. However, side effects of HRT such as increased rate of breast cancer or cervical cancer has fueled the search for a better means of decreasing bone resorption. Currently, the most popular method of reducing bone resorption is through bisphosphonate based drugs. Fosamax from Merck is the leading market contender in this class of anti-bone resorbing drugs. Another therapeutic is calcitonin which is a naturally occurring protein that inhibits osteoclast activity and is now available as a nasal spray thereby eliminating the need for injections.
The second focus for osteoporosis therapy is to stimulate osteoblast to form more bone. Clinical studies conducted using osteoporotic patients indicate that the predominant determinant of bone formation was the number of osteoblast. Fluoride (NaF) therapy fits into this category as evidence indicates that bone formation is increased with NaF treatment However, there is also evidence that increased bone mass following NaF treatment does not translate to stronger bones as the quality of bone is compromised.
A general paradigm in biology is that mature, fully differentiated cells do not divide. Therefore, to increase the number of bone producing, fully differentiated bone cells it is necessary to first increase the number of pre-osteoblast cells and then induce their maturation into fully differentiated bone cells. Two factors which occur naturally in the body are insulin-like growth factor I (IGF-I) and transforming growth factor beta (TGFB). IGF-I and TGFB are in a class of proteins known as ligands. Using isolated bone cells in culture it can be demonstrated that IGF-I acts to increase the rate of proliferation of bone cells and TGFB acts to increase the differentiation state of bone cells.
The primary function of a ligand such as IGF-I or TGFB is to activate specific receptors located on the surface of cells. IGF-I activates the IGF-I receptor and TGFB activates the TGFB receptor. As such, alternative means of activating these receptors will result in the same biological endpoints as activation by the natural ligand. A technique that has been the subject of study is the use of an electromagnetic field (also referred to as a magnetic field) to activate receptors.
An early attempt at a receptor specific electromagnetic field theory was based on the assumption that the majority of binding energy in the ligand-receptor interaction was used for specificity. For a specific ligand to find a specific receptor while millions of other molecules are present a considerable loss of entropy (randomness) and, therefore, energy is required. Assumptions were made about the strength of the chemical bonds and the cost for overcoming entropy was subtracted to yield an amount of energy. This amount of energy was hypothesized to represent the amount of energy being used by the receptor to become activated. If this receptor ‘activation’ energy were unique for a particular receptor then it would be possible to apply an electromagnetic field that would impact the required energy to a receptor and activate it. However, the electromagnetic field energy that would be required to activate a receptor from these calculations was high and thermal heating of the water surrounding a cell would interfere with any specificity. Therefore, this technique is not preferable.
Accordingly, it would be advantageous to provide a technique to stimulate cell receptor activity with lower energy electromagnetic fields.
SUMMARY
This application discloses a method and apparatus for stimulating cell receptor activity for treatment of maladies such as osteoporosis. An electromagnetic field or signal is generated by a device positioned in proximity to one or more target cell receptors, such that the flux of the electromagnetic field extends through the target receptor. The electromagnetic field is then fluctuated at a predetermined rate.
The device comprises a transmitter for generating an electromagnetic field having a predetermined rate of fluctuation and a positioning apparatus for positioning the transmitter such that the flux of the electromagnetic field extends through the target receptor.
REFERENCES:
patent: 3915151 (1975-10-01), Kraus
patent: 4266532 (1981-05-01), Ryaby et al.
patent: 4993413 (1991-02-01), McLeon
patent: 5014699 (1991-05-01), Pollack
patent: 5156587 (1992-10-01), Montone
patent: 5267939 (1993-12-01), Liboff
patent: 5318561 (1994-06-01), McLeod
patent: 5413596 (1995-05-01), Kronberg
patent: 5458558 (1995-10-01), Liboff
patent: 5743844 (1998-04-01), Tepper
patent: 5792209 (1998-08-01), Varner
patent: 5997464 (1999-12-01), Blackwell
patent: 6004257 (1999-12-01), Jacobson
patent: 6024691 (2000-02-01), Tepper et al.
patent: WO 90/07356 (1990-07-01), None
Baker & McKenzie
Cadugan Joseph A
Flaim John G.
Lacyk John P.
McSpadden William D.
LandOfFree
Stimulating cell receptor activity using electromagnetic fields does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulating cell receptor activity using electromagnetic fields, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulating cell receptor activity using electromagnetic fields will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2915378